Open AccessAntibodies to the peptide from the plasmid‐coded Yersinia outer membrane protein (YOP1) in patients with ankylosing spondylitis
Author(s) -
TSUCHIYA N.,
HUSBY G.,
WILLIAMS R. C.
Publication year - 1990
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1111/j.1365-2249.1990.tb05478.x
Subject(s) - ankylosing spondylitis , antibody , immunology , spondylitis , plasmid , medicine , biology , virology , microbiology and biotechnology , gene , genetics
SUMMARY Seventy‐five Norwegian patients with ankylosing spondylitis (AS) were studied for class‐specific antibody response against synthetic peptide, P81, representing the sequence of plasmid‐coded outer membrane protein of Yersinia (YOP1) containing four amino acid homology (TDRK) with HLA‐B27 sequence. Ten (16.7%), five (8.3%) and seven (11.2%) of 60 male AS patients showed elevated anti‐YOPI P81 antibody of IgA, IgG, and IgM class, respectively, whereas for each isotype only one (4%) of 25 healthy male controls was positive. Differences were not observed between female patients and controls. In all isotypes, antibody‐positive patients were more frequently found in patients with active disease. The anti‐YOP1 P81 antibody levels of the patients were generally not correlated with the antibody levels against the peptide representing the hypervariable region of HLA‐B27 (B27 peptide). However, in one patient the antibody was shown to react with both peptides by cross‐inhibition analysis. Overall, it appears that any causal relationship between YOP1 and pathogenesis of AS is not strong. Immunogenicity and cross‐reactivity of the YOP1 region encompassing the TDRE sequence particularly at the T cell level require further study.